Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06212427
NA

Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)

Sponsor: Société des Produits Nestlé (SPN)

View on ClinicalTrials.gov

Summary

The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose \[2'FL\] and lacto-N-neotetraose \[LNnT\], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting. A comparison with data collected retrospectively from a historical group at each site will be made for time to reach full enteral feeding, growth and adverse events. Infants in the historical group were not exposed to an HMO supplement but followed the same local nutrition protocol to avoid confounding by differences in clinical or feeding practice.

Official title: Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs): A Post-Market Study

Key Details

Gender

All

Age Range

0 Days - 14 Days

Study Type

INTERVENTIONAL

Enrollment

188

Start Date

2023-11-20

Completion Date

2026-02-28

Last Updated

2025-12-08

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

HMO supplement

Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.

Locations (6)

Kepler Universitätsklinikum Linz

Linz, Austria

Evangelisches Waldkrankenhaus Spandau

Berlin-Spandau, Germany

Kinderklinik Darmstadt

Darmstadt, Germany

Wilhelmstift Hamburg

Hamburg, Germany

Uniklinik Heidelberg

Heidelberg, Germany

Klinikum Nürnberg

Nuremberg, Germany